Cardiac Glycosides

ISBN-13: 9783540086925 / Angielski / Miękka / 1978 / 428 str.

G. Bodem; H. J. Dengler

Opis

In spite of old vintage and 200 years of clinical use, digitalis remains an interesting therapeutic agent, to clinicians as well as to the pharmacologist, the biochemist, and colleagues in other diciplines of theoretic medicine. When a drug, however, has so many attractive facets, it seems proper and aJvis able for the success of a scientific meeting to focus on a number of well-defined aspects. This symposium was devoted to pharmacokinetics, drug metabolism, analytic procedures, blood level determinations, and their interpretation both for thera peutic and toxic situations. Considerable progress has been made during the last years in this area of digitalis research. The time was suitable for a critical reap praisal of facts and theories and for future planning. Our main intention was to relate analytic data and biochemical findings to clinical problems and questions. Despite the undoubtedly basic character of clinical pharmacology, it is neverthe less an applied science which should help to develop the rational basis of thera peutics. We are particularly grateful to the active participants who bore the burden of preparing presentations and - even worse - manuscripts. At the same time we are well-aware that many other active research groups would have been able to contribute in this way, but our program was limited because of the short time available. Their knowledge is included in the discussion parts of the meeting, so we hope a well-balanced description of the present state of affairs emerged in this volume."

Spis treści

1 Evaluation of Different Methods for Determining Serum Concentrations of Cardiac Glycosides.- 2 A New Simple Assay for Determining Digoxin Serum Levels.- 3 Chloroform-Extractable and Polar Metabolites Examined With Different Assays.- 4 Studies of the Metabolism of Digoxin and Digitoxin Using Double Isotope Dilution Derivative Methods.- 5 Occurence and Chemical Nature of Polar Water-Soluble Digoxin Metabolites.- 6 Pharmacokinetics and Metabolism of Digitoxin in the Human.- 7 Dihydrodigitoxin, a Metabolite of Digitoxin in Humans.- 8 Enterohepatic Circulation of Digitoxin Metabolites in the Dog.- 9 ?-Methyl-Digoxin, a New Lipophilic Digoxin Derivative.- 10 Tissue Distribution of Cardiac Glycosides.- 11 Plasma-Tissue Distribution of Different Cardiac Glycosides.- 12 Significance of Plasma Concentration of Digoxin in Relation to the Myocardial Concentration of the Drug.- 13 Influence of Thyroid Function on the Pharmacokinetics of Cardiac Glycosides.- 14 Effect of Jejunoileal Bypass on the Bioavailability of Digoxin in Man.- 15 Bioavailability of Digoxin in Renal Insufficiency and Heart Failure.- 16 Bioavailability Studies: Their Influence on the Clinical Use of Digitalis.- 17 Comparative Pharmacokinetics of Various Digoxin Preparations in Man.- 18 Digoxin Pharmacokinetics and Their Relation to Clinical Dosage Parameters.- 19 Clinical Interpretation of Serum Concentrations of Cardiac Glycosides.- 20 Assessment of Digoxin Action by a Pharmacodynamic Biochemical Method.- 21 Relationships Between Doses, Plasma Levels and Cardiac Effects Under Digitalis Treatment.- 22.1 Therapeutic Implications of Digoxin Kinetics in Impaired Renal Function.- 22.2 Peak Plasma Digoxin Concentration and Cardiotoxicity.- 22.3 Biliary Excretion of ?-Acetyl-Digoxin in Man.- 23 Digitoxin Pharmacokinetics in Patients With Renal Disease.- 24 Increased Digitalis Tolerance in Uremic Patients.- 25 Digitoxin and Digoxin in Patients With Chronic Renal Failure and on Hemodialysis.- 26 International Patterns of Clinical Use and Toxicity of Digitalis Glycosides: Report From the Boston Collaborative Drug Surveillance Program.- 27 Pharmacokinetic and Clinical Effects During the Predistribution Phase of Digoxin Treatment.- 28 Digitalis Intoxication: Clinical and Experimental Work.- 29 Digitalis Intoxication: Specificity of Clinical and Electrocardiographic Signs.- 30 Treatment of Digitalis Intoxication.- 31 Biologic Effects of Specific Antibodies in Reversing the Pharmacologic and Toxic Effects of Digoxin.- 32 Reversal of Digitoxin Toxicity and Modification of Pharmacokinetics by Specific Antibodies.- 33 ?-Methyl-Digoxin Disposition During Spironolactone Treatment.- 34 Digitoxin Disposition Under Rifampicin Treatment.- 35 Is There a Need for New Cardiac Glycosides? For More Blood Level Determinations?.